» Articles » PMID: 9202004

Activating Transcription Factor 2 (ATF2) Down-regulates Hepatitis B Virus X Promoter Activity by the Competition for the Activating Protein 1 Binding Site and the Formation of the ATF2-Jun Heterodimer

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1997 Jul 4
PMID 9202004
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The hepatitis B viral X promoter is known to be positively autoregulated by its own HBx protein, which also interacts with many cellular regulatory proteins. We investigated the effect of activating transcription factor 2 (ATF2) on the activity of the X promoter. Cotransfection of the ATF2 expression vector with a X promoter-chloramphenicol acetyltransferase plasmid repressed the X promoter activity in HepG2 cells. HBx activated activating protein 1 (AP-1)-mediated transcription through the hepatitis B virus E element by 35-fold, while its activation activity was inhibited in the presence of ATF2, suggesting that ATF2 inhibited the autoactivation of X promoter by HBx and basal transcription mediated by AP-1. Since the binding sites of AP-1 and ATF2 in the hepatitis B virus E element overlap, the repression of X promoter activity by ATF2 is exerted by the competition for the AP-1 binding site and the formation of the ATF2-Jun heterodimer as in the case of the consensus AP-1 element. However, the small X promoter had a ATF2 binding site and was activated by ATF2. These results suggest that the syntheses of X proteins are differentially regulated by ATF2.

Citing Articles

SIAH2 suppresses c-JUN pathway by promoting the polyubiquitination and degradation of HBx in hepatocellular carcinoma.

Hu Q, Liu Z, Liu Y, Qiu J, Zhang X, Sun J J Cell Mol Med. 2024; 28(11):e18484.

PMID: 38842124 PMC: 11154841. DOI: 10.1111/jcmm.18484.


Forthcoming Developments in Models to Study the Hepatitis B Virus Replication Cycle, Pathogenesis, and Pharmacological Advancements.

Bhat S, Ahanger I, Kazim S ACS Omega. 2023; 8(16):14273-14289.

PMID: 37125123 PMC: 10134252. DOI: 10.1021/acsomega.2c07154.


HBV cccDNA-A Culprit and Stumbling Block for the Hepatitis B Virus Infection: Its Presence in Hepatocytes Perplexed the Possible Mission for a Functional Cure.

Bhat S, Kazim S ACS Omega. 2022; 7(28):24066-24081.

PMID: 35874215 PMC: 9301636. DOI: 10.1021/acsomega.2c02216.


The Hepatitis B Virus Interactome: A Comprehensive Overview.

Van Damme E, Vanhove J, Severyn B, Verschueren L, Pauwels F Front Microbiol. 2021; 12:724877.

PMID: 34603251 PMC: 8482013. DOI: 10.3389/fmicb.2021.724877.


Silencing hepatitis B virus covalently closed circular DNA: The potential of an epigenetic therapy approach.

Singh P, Kairuz D, Arbuthnot P, Bloom K World J Gastroenterol. 2021; 27(23):3182-3207.

PMID: 34163105 PMC: 8218364. DOI: 10.3748/wjg.v27.i23.3182.